Kura Oncology Officer Plans $97K Share Sale

The preceding three months included two listed restricted-stock-unit sales, reported at $51,663.26 and $84,497.61.

Rhea-AI Filing Summary

Kura Oncology, Inc. officer Brian T. Powl reported an intended sale of 9,020 common shares, with an aggregate market value of $97,055.20 and a planned sale date of September 28, 2026. The shares are listed as acquired from the issuer through restricted stock units on September 27, 2026. Kura Oncology had 91,869,597 shares outstanding as of September 28, 2026.

Sales listed for Powl during the preceding three months included 4,345 restricted stock units on August 21, 2026, with a reported value of $51,663.26, and 8,000 on September 28, 2026, with a reported value of $84,497.61.

Key Figures

Common shares intended for sale: 9,020 shares Aggregate market value: $97,055.20 Shares outstanding: 91,869,597 shares +4 more

7 metrics

Common shares intended for sale 9,020 shares Planned sale date: September 28, 2026

Aggregate market value $97,055.20 Intended sale of 9,020 common shares

Shares outstanding 91,869,597 shares As of September 28, 2026

Restricted stock units sold 4,345 shares August 21, 2026

Reported value $51,663.26 Sale listed for August 21, 2026

Restricted stock units sold 8,000 shares September 28, 2026

Reported value $84,497.61 Sale listed for September 28, 2026

Key Terms

Rule 144, Restricted Stock Units, 10b5-1 Sales

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Restricted Stock Units | 08/21/2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for Brian Powl"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KURA shares did Brian Powl plan to sell?

Brian T. Powl, an officer of Kura Oncology (KURA), reported an intended sale of 9,020 common shares with an aggregate market value of $97,055.20. The planned sale date is September 28, 2026.

What KURA shares did Brian Powl sell in the prior three months?

Sales listed for Brian T. Powl during the preceding three months included 4,345 restricted stock units on August 21, 2026, with a reported value of $51,663.26, and 8,000 restricted stock units on September 28, 2026, with a reported value of $84,497.61. The sales are identified as 10b5-1 sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 09:00 PM Accepted by SEC EDGAR 09/28/2026 - 09:00 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001934232
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KURA ONCOLOGY, INC.
SEC File Number	001-37620
Address of Issuer	4930 Directors Place, Suite 500 San Diego CALIFORNIA 92121
Phone	(858)-500-8800
Name of Person for Whose Account the Securities are To Be Sold	POWL BRIAN T
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9020	97055.20	91869597	09/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/27/2026	RSU	Issuer			9020	09/28/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for Brian Powl 4930 Directors Place Suite 500 San Diego CA 92121	Restricted Stock Units	08/21/2026	4345	51663.26
10b5-1 Sales for Brian Powl 4930 Directors Place Suite 500 San Diego CA 92121	Restricted Stock Units	09/28/2026	8000	84497.61

144: Remarks and Signature

Remarks
Date of Notice	09/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Teresa Bair, Attorney-in-fact for Brian Powl
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)